Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 27 entries
Sorted by: Best Match Show Resources per page
A voluminous mass as an initial clinical symptom of multiple myeloma: A case report.

Experimental and therapeutic medicine

Sgherza N, Iacobazzi A, Cramarossa A, DE Tullio G, Guarini A.
PMID: 26640537
Exp Ther Med. 2015 Nov;10(5):1689-1691. doi: 10.3892/etm.2015.2720. Epub 2015 Sep 01.

Extramedullary multiple myeloma (EMM) is a type of multiple myeloma (MM) that is defined by the presence of extraskeletal (soft tissue or visceral) clonal plasma cell infiltrates, which may be present at the time of initial diagnosis or at...

Cite
Sgherza N, Iacobazzi A, Cramarossa A, et al. A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. Exp Ther Med. 2015;10(5):1689-1691doi: 10.3892/etm.2015.2720.
Sgherza, N., Iacobazzi, A., Cramarossa, A., DE Tullio, G., & Guarini, A. (2015). A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. Experimental and therapeutic medicine, 10(5), 1689-1691. https://doi.org/10.3892/etm.2015.2720
Sgherza, Nicola, et al. "A voluminous mass as an initial clinical symptom of multiple myeloma: A case report." Experimental and therapeutic medicine vol. 10,5 (2015): 1689-1691. doi: https://doi.org/10.3892/etm.2015.2720
Sgherza N, Iacobazzi A, Cramarossa A, DE Tullio G, Guarini A. A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. Exp Ther Med. 2015 Nov;10(5):1689-1691. doi: 10.3892/etm.2015.2720. Epub 2015 Sep 01. PMID: 26640537; PMCID: PMC4665678.
Copy Download .nbib Format: NLM
Effective implantation of autologous chondrocytes in a patient suffering from a painful and invalidating rizoarthrosis: a case report.

Cases journal

Carelli F, Sgherzi S, Sillani A, Magris C.
PMID: 19918494
Cases J. 2009 Aug 18;2:7886. doi: 10.4076/1757-1626-2-7886.

A 45-year-old patient, caucasian, affected by severe, painful and invalidating rizoarthrosis has been treated by implanting autologous chondrocytes, normally used for degenerative joint diseases of the knee and ankle.

Cite
Carelli F, Sgherzi S, Sillani A, et al. Effective implantation of autologous chondrocytes in a patient suffering from a painful and invalidating rizoarthrosis: a case report. Cases J. 2009;2:7886doi: 10.4076/1757-1626-2-7886.
Carelli, F., Sgherzi, S., Sillani, A., & Magris, C. (2009). Effective implantation of autologous chondrocytes in a patient suffering from a painful and invalidating rizoarthrosis: a case report. Cases journal, 27886. https://doi.org/10.4076/1757-1626-2-7886
Carelli, Francesco, et al. "Effective implantation of autologous chondrocytes in a patient suffering from a painful and invalidating rizoarthrosis: a case report." Cases journal vol. 2 (2009): 7886. doi: https://doi.org/10.4076/1757-1626-2-7886
Carelli F, Sgherzi S, Sillani A, Magris C. Effective implantation of autologous chondrocytes in a patient suffering from a painful and invalidating rizoarthrosis: a case report. Cases J. 2009 Aug 18;2:7886. doi: 10.4076/1757-1626-2-7886. PMID: 19918494; PMCID: PMC2769384.
Copy Download .nbib Format: NLM
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma.

medRxiv : the preprint server for health sciences

Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF.
PMID: 34981068
medRxiv. 2021 Dec 21; doi: 10.1101/2021.12.10.21267485.

BACKGROUND: The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain.METHODS: This multicenter, double-blind randomized controlled trial compared the efficacy and safety of SARS-CoV-2 high titer...

Cite
Sullivan DJ, Gebo KA, Shoham S, et al. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv. 2021;doi: 10.1101/2021.12.10.21267485.
Sullivan, D. J., Gebo, K. A., Shoham, S., Bloch, E. M., Lau, B., Shenoy, A. G., Mosnaim, G. S., Gniadek, T. J., Fukuta, Y., Patel, B., Heath, S. L., Levine, A. C., Meisenberg, B. R., Spivak, E. S., Anjan, S., Huaman, M. A., Blair, J. E., Currier, J. S., Paxton, J. H., Gerber, J. M., Petrini, J. R., Broderick, P. B., Rausch, W., Cordisco, M. E., Hammel, J., Greenblatt, B., Cluzet, V. C., Cruser, D., Oei, K., Abinante, M., Hammitt, L. L., Sutcliffe, C. G., Forthal, D. N., Zand, M. S., Cachay, E. R., Raval, J. S., Kassaye, S. G., Foster, E. C., Roth, M., Marshall, C. E., Yarava, A., Lane, K., McBee, N. A., Gawad, A. L., Karlen, N., Singh, A., Ford, D. E., Jabs, D. A., Appel, L. J., Shade, D. M., Ehrhardt, S., Baksh, S. N., Laeyendecker, O., Pekosz, A., Klein, S. L., Casadevall, A., Tobian, A. A. R., & Hanley, D. F. (2021). Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.12.10.21267485
Sullivan, David J, et al. "Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.12.10.21267485
Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv. 2021 Dec 21; doi: 10.1101/2021.12.10.21267485. PMID: 34981068; PMCID: PMC8722611.
Copy Download .nbib Format: NLM
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.

Blood cancer journal

Sgherza N, Curci P, Rizzi R, Attolico I, Loconsole D, Mestice A, Chironna M, Musto P.
PMID: 34907155
Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y.

No abstract available.

Cite
Sgherza N, Curci P, Rizzi R, et al. SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma. Blood Cancer J. 2021;11(12):201doi: 10.1038/s41408-021-00597-y.
Sgherza, N., Curci, P., Rizzi, R., Attolico, I., Loconsole, D., Mestice, A., Chironna, M., & Musto, P. (2021). SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma. Blood cancer journal, 11(12), 201. https://doi.org/10.1038/s41408-021-00597-y
Sgherza, Nicola, et al. "SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma." Blood cancer journal vol. 11,12 (2021): 201. doi: https://doi.org/10.1038/s41408-021-00597-y
Sgherza N, Curci P, Rizzi R, Attolico I, Loconsole D, Mestice A, Chironna M, Musto P. SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma. Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y. PMID: 34907155; PMCID: PMC8669415.
Copy Download .nbib Format: NLM
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.

Blood cancer journal

Sgherza N, Curci P, Rizzi R, Attolico I, Loconsole D, Mestice A, Chironna M, Musto P.
PMID: 34907155
Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y.

No abstract available.

Cite
Sgherza N, Curci P, Rizzi R, et al. SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma. Blood Cancer J. 2021;11(12):201doi: 10.1038/s41408-021-00597-y.
Sgherza, N., Curci, P., Rizzi, R., Attolico, I., Loconsole, D., Mestice, A., Chironna, M., & Musto, P. (2021). SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma. Blood cancer journal, 11(12), 201. https://doi.org/10.1038/s41408-021-00597-y
Sgherza, Nicola, et al. "SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma." Blood cancer journal vol. 11,12 (2021): 201. doi: https://doi.org/10.1038/s41408-021-00597-y
Sgherza N, Curci P, Rizzi R, Attolico I, Loconsole D, Mestice A, Chironna M, Musto P. SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma. Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y. PMID: 34907155.
Copy Download .nbib Format: NLM
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study.

Haematologica

Sgherza N, Curci P, Rizzi R, Strafella V, Di Gennaro D, Vitucci A, Palma A, Rossi AVR, Albano F, Stefanizzi P, Tafuri S, Musto P.
PMID: 34732044
Haematologica. 2021 Nov 04; doi: 10.3324/haematol.2021.279895. Epub 2021 Nov 04.

Not available.

Cite
Sgherza N, Curci P, Rizzi R, et al. Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study. Haematologica. 2021;doi: 10.3324/haematol.2021.279895.
Sgherza, N., Curci, P., Rizzi, R., Strafella, V., Di Gennaro, D., Vitucci, A., Palma, A., Rossi, A. V. R., Albano, F., Stefanizzi, P., Tafuri, S., & Musto, P. (2021). Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study. Haematologica, . https://doi.org/10.3324/haematol.2021.279895
Sgherza, Nicola, et al. "Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study." Haematologica vol. (2021). doi: https://doi.org/10.3324/haematol.2021.279895
Sgherza N, Curci P, Rizzi R, Strafella V, Di Gennaro D, Vitucci A, Palma A, Rossi AVR, Albano F, Stefanizzi P, Tafuri S, Musto P. Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study. Haematologica. 2021 Nov 04; doi: 10.3324/haematol.2021.279895. Epub 2021 Nov 04. PMID: 34732044.
Copy Download .nbib Format: NLM
Residual Peripheral Blood CD26.

Frontiers in oncology

Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D.
PMID: 29900128
Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018.

Chronic myeloid leukemia (CML) patients in sustained "deep molecular response" may stop TKI treatment without disease recurrence; however, half of them lose molecular response shortly after TKI withdrawing. Well-defined eligibility criteria to predict a safe discontinuation up-front are still...

Cite
Bocchia M, Sicuranza A, Abruzzese E, et al. Residual Peripheral Blood CD26. Front Oncol. 2018;8:194doi: 10.3389/fonc.2018.00194.
Bocchia, M., Sicuranza, A., Abruzzese, E., Iurlo, A., Sirianni, S., Gozzini, A., Galimberti, S., Aprile, L., Martino, B., Pregno, P., Sorà, F., Alunni, G., Fava, C., Castagnetti, F., Puccetti, L., Breccia, M., Cattaneo, D., Defina, M., Mulas, O., Baratè, C., Caocci, G., Sica, S., Gozzetti, A., Luciano, L., Crugnola, M., Annunziata, M., Tiribelli, M., Pacelli, P., Ferrigno, I., Usala, E., Sgherza, N., Rosti, G., Bosi, A., & Raspadori, D. (2018). Residual Peripheral Blood CD26. Frontiers in oncology, 8194. https://doi.org/10.3389/fonc.2018.00194
Bocchia, Monica, et al. "Residual Peripheral Blood CD26." Frontiers in oncology vol. 8 (2018): 194. doi: https://doi.org/10.3389/fonc.2018.00194
Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D. Residual Peripheral Blood CD26. Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018. PMID: 29900128; PMCID: PMC5988870.
Copy Download .nbib Format: NLM
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.

Journal of clinical medicine

Dragani M, Rege Cambrin G, Berchialla P, Dogliotti I, Rosti G, Castagnetti F, Capodanno I, Martino B, Cerrano M, Ferrero D, Gambacorti-Passerini C, Crugnola M, Elena C, Breccia M, Iurlo A, Cattaneo D, Galimberti S, Gozzini A, Bocchia M, Lunghi F, Cedrone M, Sgherza N, Luciano L, Russo S, Santoro M, Giai V, Caocci G, Levato L, Abruzzese E, Sora F, Saglio G, Fava C.
PMID: 33213044
J Clin Med. 2020 Nov 17;9(11). doi: 10.3390/jcm9113692.

Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in...

Cite
Dragani M, Rege Cambrin G, Berchialla P, et al. A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. J Clin Med. 2020;9(11)doi: 10.3390/jcm9113692.
Dragani, M., Rege Cambrin, G., Berchialla, P., Dogliotti, I., Rosti, G., Castagnetti, F., Capodanno, I., Martino, B., Cerrano, M., Ferrero, D., Gambacorti-Passerini, C., Crugnola, M., Elena, C., Breccia, M., Iurlo, A., Cattaneo, D., Galimberti, S., Gozzini, A., Bocchia, M., Lunghi, F., Cedrone, M., Sgherza, N., Luciano, L., Russo, S., Santoro, M., Giai, V., Caocci, G., Levato, L., Abruzzese, E., Sora, F., Saglio, G., & Fava, C. (2020). A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. Journal of clinical medicine, 9(11), . https://doi.org/10.3390/jcm9113692
Dragani, Matteo, et al. "A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation." Journal of clinical medicine vol. 9,11 (2020). doi: https://doi.org/10.3390/jcm9113692
Dragani M, Rege Cambrin G, Berchialla P, Dogliotti I, Rosti G, Castagnetti F, Capodanno I, Martino B, Cerrano M, Ferrero D, Gambacorti-Passerini C, Crugnola M, Elena C, Breccia M, Iurlo A, Cattaneo D, Galimberti S, Gozzini A, Bocchia M, Lunghi F, Cedrone M, Sgherza N, Luciano L, Russo S, Santoro M, Giai V, Caocci G, Levato L, Abruzzese E, Sora F, Saglio G, Fava C. A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. J Clin Med. 2020 Nov 17;9(11). doi: 10.3390/jcm9113692. PMID: 33213044; PMCID: PMC7698481.
Copy Download .nbib Format: NLM
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL).

HemaSphere

Tisi MC, Ferrero S, Dogliotti I, Tecchio C, Carli G, Novo M, Stefani PM, Rattotti S, Balzarotti M, Marino D, Pelosini M, Romano A, Flenghi L, Zilioli VR, Calimeri T, Di Napoli A, Zanni M, Finolezzi E, Mosna F, Gini G, Mansueto G, Di Rocco A, Tomei G, Sgherza N, Olivieri J, Nassi L, Piazza F, Fama A, Greco A, Giannoccaro M, Mazzone AM, Visco C, Loseto G, Zaja F.
PMID: 31976479
Hemasphere. 2019 Oct 22;3(6):e305. doi: 10.1097/HS9.0000000000000305. eCollection 2019 Dec.

No abstract available.

Cite
Tisi MC, Ferrero S, Dogliotti I, et al. MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). Hemasphere. 2019;3(6):e305doi: 10.1097/HS9.0000000000000305.
Tisi, M. C., Ferrero, S., Dogliotti, I., Tecchio, C., Carli, G., Novo, M., Stefani, P. M., Rattotti, S., Balzarotti, M., Marino, D., Pelosini, M., Romano, A., Flenghi, L., Zilioli, V. R., Calimeri, T., Di Napoli, A., Zanni, M., Finolezzi, E., Mosna, F., Gini, G., Mansueto, G., Di Rocco, A., Tomei, G., Sgherza, N., Olivieri, J., Nassi, L., Piazza, F., Fama, A., Greco, A., Giannoccaro, M., Mazzone, A. M., Visco, C., Loseto, G., & Zaja, F. (2019). MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). HemaSphere, 3(6), e305. https://doi.org/10.1097/HS9.0000000000000305
Tisi, Maria Chiara, et al. "MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)." HemaSphere vol. 3,6 (2019): e305. doi: https://doi.org/10.1097/HS9.0000000000000305
Tisi MC, Ferrero S, Dogliotti I, Tecchio C, Carli G, Novo M, Stefani PM, Rattotti S, Balzarotti M, Marino D, Pelosini M, Romano A, Flenghi L, Zilioli VR, Calimeri T, Di Napoli A, Zanni M, Finolezzi E, Mosna F, Gini G, Mansueto G, Di Rocco A, Tomei G, Sgherza N, Olivieri J, Nassi L, Piazza F, Fama A, Greco A, Giannoccaro M, Mazzone AM, Visco C, Loseto G, Zaja F. MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). Hemasphere. 2019 Oct 22;3(6):e305. doi: 10.1097/HS9.0000000000000305. eCollection 2019 Dec. PMID: 31976479; PMCID: PMC6924554.
Copy Download .nbib Format: NLM
What Is New in the Treatment of Smoldering Multiple Myeloma?.

Journal of clinical medicine

Bolli N, Sgherza N, Curci P, Rizzi R, Strafella V, Delia M, Gagliardi VP, Neri A, Baldini L, Albano F, Musto P.
PMID: 33499196
J Clin Med. 2021 Jan 22;10(3). doi: 10.3390/jcm10030421.

Smoldering multiple myeloma (SMM), an asymptomatic plasma cell neoplasm, is currently diagnosed according to the updated IMWG criteria, which reflect an intermediate tumor mass between monoclonal gammopathy of undetermined significance (MGUS) and active MM. However, SMM is a heterogeneous...

Cite
Bolli N, Sgherza N, Curci P, et al. What Is New in the Treatment of Smoldering Multiple Myeloma?. J Clin Med. 2021;10(3)doi: 10.3390/jcm10030421.
Bolli, N., Sgherza, N., Curci, P., Rizzi, R., Strafella, V., Delia, M., Gagliardi, V. P., Neri, A., Baldini, L., Albano, F., & Musto, P. (2021). What Is New in the Treatment of Smoldering Multiple Myeloma?. Journal of clinical medicine, 10(3), . https://doi.org/10.3390/jcm10030421
Bolli, Niccolo', et al. "What Is New in the Treatment of Smoldering Multiple Myeloma?." Journal of clinical medicine vol. 10,3 (2021). doi: https://doi.org/10.3390/jcm10030421
Bolli N, Sgherza N, Curci P, Rizzi R, Strafella V, Delia M, Gagliardi VP, Neri A, Baldini L, Albano F, Musto P. What Is New in the Treatment of Smoldering Multiple Myeloma?. J Clin Med. 2021 Jan 22;10(3). doi: 10.3390/jcm10030421. PMID: 33499196; PMCID: PMC7865294.
Copy Download .nbib Format: NLM
[High prevalence of masked uncontrolled arterial hypertension in patients under therapy].

Praxis

Scherz N.
PMID: 25711791
Praxis (Bern 1994). 2015 Feb 25;104(5):257-8. doi: 10.1024/1661-8157/a001939.

No abstract available.

Cite
Scherz N. Hohe Prävalenz der maskierten unkontrollierten arteriellen Hypertonie bei Patienten unter Therapie. [High prevalence of masked uncontrolled arterial hypertension in patients under therapy]. Praxis (Bern 1994). 2015;104(5):257-8doi: 10.1024/1661-8157/a001939.
Scherz, N. (2015). Hohe Prävalenz der maskierten unkontrollierten arteriellen Hypertonie bei Patienten unter Therapie. [High prevalence of masked uncontrolled arterial hypertension in patients under therapy]. Praxis, 104(5), 257-8. https://doi.org/10.1024/1661-8157/a001939
Scherz, Nathalie. "Hohe Prävalenz der maskierten unkontrollierten arteriellen Hypertonie bei Patienten unter Therapie." [High prevalence of masked uncontrolled arterial hypertension in patients under therapy]. Praxis vol. 104,5 (2015): 257-8. doi: https://doi.org/10.1024/1661-8157/a001939
Scherz N. Hohe Prävalenz der maskierten unkontrollierten arteriellen Hypertonie bei Patienten unter Therapie. [High prevalence of masked uncontrolled arterial hypertension in patients under therapy]. Praxis (Bern 1994). 2015 Feb 25;104(5):257-8. doi: 10.1024/1661-8157/a001939. German. PMID: 25711791.
Copy Download .nbib Format: NLM
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.

Frontiers in oncology

Sgherza N, Curci P, Rizzi R, Musto P.
PMID: 34660279
Front Oncol. 2021 Sep 30;11:716751. doi: 10.3389/fonc.2021.716751. eCollection 2021.

Although the survival rate of patients with multiple myeloma has significantly improved in the last years thanks to the introduction of various classes of new drugs, such as proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies, the vast majority of...

Cite
Sgherza N, Curci P, Rizzi R, et al. Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor. Front Oncol. 2021;11:716751doi: 10.3389/fonc.2021.716751.
Sgherza, N., Curci, P., Rizzi, R., & Musto, P. (2021). Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor. Frontiers in oncology, 11716751. https://doi.org/10.3389/fonc.2021.716751
Sgherza, Nicola, et al. "Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor." Frontiers in oncology vol. 11 (2021): 716751. doi: https://doi.org/10.3389/fonc.2021.716751
Sgherza N, Curci P, Rizzi R, Musto P. Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor. Front Oncol. 2021 Sep 30;11:716751. doi: 10.3389/fonc.2021.716751. eCollection 2021. PMID: 34660279; PMCID: PMC8514936.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 27 entries